Healthcare -
Drug Manufacturers - General - NYSE - US
$ 723.73
-1.96 %
$ 686 B
Market Cap
61.65
P/E
1. INTRINSIC VALUE
Balance Sheet
Eli Lilly and Company
| Current Assets | 3.52 B |
| Cash & Short-Term Investments | 3.27 B |
| Receivables | 0 |
| Other Current Assets | 250 M |
| Non-Current Assets | 46 B |
| Long-Term Investments | 3.22 B |
| PP&E | 17.1 B |
| Other Non-Current Assets | 25.7 B |
| Current Liabilities | 28.4 B |
| Accounts Payable | 0 |
| Short-Term Debt | 0 |
| Other Current Liabilities | 28.4 B |
| Non-Current Liabilities | 36.1 B |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 36.1 B |
EFFICIENCY
Earnings Waterfall
Eli Lilly and Company
| Revenue | 45 B |
| Cost Of Revenue | 8.42 B |
| Gross Profit | 36.6 B |
| Operating Expenses | 36.6 B |
| Operating Income | 12.9 B |
| Other Expenses | 2.31 B |
| Net Income | 10.6 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Eli Lilly and Company
| Net Income | 10.6 B |
| Depreciation & Amortization | 1.77 B |
| Capital Expenditures | -8.4 B |
| Stock-Based Compensation | 646 M |
| Change in Working Capital | 0 |
| Others | 265 M |
| Free Cash Flow | 414 M |
Wall Street Analysts Price Targets
Eli Lilly and Company
Wall Street analysts predict an average 1-year price target for LLY of $986 , with forecasts ranging from
a
low of
$785 to a high of $1.15 K.
LLY Lowest Price Target
Wall Street Target
785 USD
8.47%
LLY Average Price Target
Wall Street Target
986 USD
36.21%
LLY Highest Price Target
Wall Street Target
1.15 K USD
58.90%
4. DIVIDEND
ANALYSIS
0.17%
DIVIDEND YIELD
1.5 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Eli Lilly and Company
Sold
0-3 MONTHS
2.39 B USD 3
3-6 MONTHS
723 K USD 1
6-9 MONTHS
50.9 M USD 2
9-12 MONTHS
1.69 B USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Eli Lilly And Novo Nordisk Could Face Policy Shifts As FDA Oversight, Tariff Risks Mount
Needham hosted Spencer Perlman, director of Healthcare Research at Veda Partners, an investment advisory and consulting firm with extensive expertise in government policy analysis. During the conversation, analyst Gil Blum discussed several topics of interest, including trade tariffs, recent personnel changes in the FDA/HHS, 503A/503B compounding related to GLP-1s, the FTC and their potential impact on healthcare equities.
benzinga.com
- 1 week ago
NVO & LLY Shares Down on Exclusion of Obesity Drugs From Medicare
CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they are solely prescribed for weight loss.
zacks.com
- 1 week ago
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
zacks.com
- 1 week ago
2 Top Growth Stocks to Buy and Hold for the Next 20 Years
One of the keys to successful investing is holding shares of companies that can perform well over long periods. However, few companies can thrive for that long while delivering excellent returns to investors.
fool.com
- 1 week ago
3 Dividend Stocks to Buy and Hold for the Next Decade
What should investors do when stocks are tanking over the short term? Probably the best answer is to think long term.
fool.com
- 1 week ago
Eli Lilly, Novo Stocks Dive After Medicare Excludes Weight-Loss Drugs
The Trump administration finalized new Medicare and Medicaid policies late Friday, but left out weight-loss drugs. Eli Lilly stock skidded.
investors.com
- 2 weeks ago
Trump drops Biden's proposal for Medicare to cover obesity drugs like Wegovy and Zepbound
President Donald Trump dropped a Biden administration proposal to have Medicare cover obesity drugs, including popular GLP-1 treatments such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. But the Centers for Medicare and Medicaid Services said it may reconsider coverage of those drugs in the future, according to a fact sheet on the rule.
cnbc.com
- 2 weeks ago
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal
Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payments. The Fabry Disease gene therapy program, with phase 1/2 STAAR study data expected in 1H 2025, is a major near-term catalyst for investors to keep an eye on. Positive eGFR slope data could lead to an Accelerated Approval filing of isaralgagene civaparvovec for Fabry Disease in the 2nd half of 2025.
seekingalpha.com
- 2 weeks ago
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
seekingalpha.com
- 2 weeks ago
These 5 S&P 500 Stocks Are Growing Revenue The Most Right Now
These 5 companies will have minimal impact from the tariffs and could deliver strong results in 2025.
247wallst.com
- 2 weeks ago
PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.
zacks.com
- 2 weeks ago
Why April Could Be a Huge Month for Eli Lilly Stock
Eli Lilly (LLY -2.70%) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 months, however, the stock's performance has been fairly lackluster, rising by just around 6%.
fool.com
- 2 weeks ago
8. Profile
Summary
Eli Lilly and Company LLY
COUNTRY
US
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 686 B
Dividend Yield
0.17%
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Contact
Lilly Corporate Center, Indianapolis, IN, 46285
https://www.lilly.com
IPO
Date
June 1, 1972
Employees
47000
Officers
Mr. Lucas E. Montarce
Executive Vice President & Chief Financial Officer
Dr. Daniel M. Skovronsky M.D., Ph.D.
EVice President, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology
Mr. Jacob S. Van Naarden
Executive Vice President & President of Loxo
Mr. Donald A. Zakrowski
Senior Vice President of Finance & Chief Accounting Officer
Mr. Jeffrey N. Simmons
Senior Vice President & President of Elanco Animal Health
Mr. David A. Ricks
Chairman, Chief Executive Officer & President
Ms. Anat Hakim J.D.
Executive Vice President, General Counsel & Secretary
Mr. Diogo Rau
EVice President & Chief Information and Digital Officer
Mr. Gordon Brooks
Group Vice President, Controller & Corporate Strategy
Mr. Eric Dozier
Executive Vice President of Human Resources & Diversity